Thursday, February 11, 2016

Dipexium reaches 75% enrolment in Phase 3 trials

Dipexium reaches 75% enrolment in Phase 3 trials

February 4, 2016 by · Leave a Comment 

Tweet Dipexium Pharmaceuticals’ (NASDAQ:DPRX) OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone in total, with each study having enrolled nearly the same number of patients. OneStep-1 and OneStep-2 are identical Phase 3 trials, with 180 patients per clinical trial. They are being conducted under a SPA with the FDA […]

Leerink downgrades Carbylan to market perform

Leerink downgrades Carbylan to market perform

February 2, 2016 by · Leave a Comment 

Tweet Leerink Partners has downgraded Carbylan Therapeutics (NASDAQ:CBYL) to “market perform” from “outperform” and slashed its price target to $1.83 from $15 after the company reported a disappointing Phase 3 readout for Hydros-TA in the COR 1.1 trial. The shares were down 46% to $1.33 in after-market trading on Monday. The company’s lead program, Hydros-TA, […]

Knight to sublicense Titan Pharma’s Probuphine in Canada

Knight to sublicense Titan Pharma’s Probuphine in Canada

February 1, 2016 by · Leave a Comment 

Tweet Titan Pharmaceuticals’ (NASDAQ:TTNP) development and marketing partner, closely-held Braeburn Pharmaceuticals, and Knight Therapeutics (TSX:GUD) have entered into an agreement, giving Knight exclusive rights to commercialize Titan’s Probuphine in Canada. Probuphine is an investigational subdermal implant designed to deliver buprenorphine continuously for six months following a single treatment, promoting patient compliance and retention, as well […]

Transition Therapeutics reports TT401 trial results

Transition Therapeutics reports TT401 trial results

February 1, 2016 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has reported results of a Phase 2 clinical study of drug candidate, TT401, for the treatment of Type 2 diabetes. TT401 is a once-weekly administered oxyntomodulin analog, with dual GLP-1 and glucagon agonist activity. TT401 development collaborator, Eli Lilly, performed the Phase 2 study, enrolling 420 Type 2 diabetes subjects […]

Rodman starts VolitionRx at buy

Rodman starts VolitionRx at buy

February 1, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of VolitionRx (NASDAQ:VNRX) with a “buy” rating and a 12-month price target of $12. The stock closed at $3.77 on Friday. “In our view, the company’s blood-based NuQ screening test for colorectal cancer, based on its proprietary nucleosomics epigenetic biomarker platform, is differentiated from traditional detection methods and […]

Rodman starts EyeGate Pharma at buy

Rodman starts EyeGate Pharma at buy

February 1, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has launched coverage of EyeGate Pharmaceuticals (NASDAQ:EYEG) with a “buy’ rating and a 12-month price target of $10. The stock closed at $1.70 on Friday. “In our view, the company’s EGP-437 combination product is differentiated from eye drops and intraocular injections in that it is non-invasive and solves patient non-compliance and […]

Dipexium Pharma gets Locilex patents in Australia and NZ

Dipexium Pharma gets Locilex patents in Australia and NZ

February 1, 2016 by · Leave a Comment 

Tweet Dipexium Pharmaceuticals (NASDAQ:DPRX) said that Australia and New Zealand have issued new Locilex patents, with expiry dates in June 2033. The patents’ claims are directed to a novel formulation of Locilex, an antibiotic peptide formulated as a topical cream, and use of Locilex as a method of treating skin or wound infections. “These patents […]

TearLab estimates Q4 revenue rose 28%

TearLab estimates Q4 revenue rose 28%

February 1, 2016 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) expects to report revenue of approximately $6.8-million for the fourth quarter of 2015, up about 28% from the same quarter in 2014. In addition, TearLab estimated that a net total of 258 TearLab Osmolality Systems were added in the fourth quarter of 2015, of which 200 were under the company’s new […]

Rodman starts BioBlast Pharma at buy

Rodman starts BioBlast Pharma at buy

January 28, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of BioBlast Pharma (NASDAQ:ORPN) with a “buy” rating and 12-month price target of $25. The stock closed at $3.24 on Wednesday. BioBlast is focused on platform-based solutions, addressing rare diseases due to mitochondrial dysfunction and misfolding of critical function proteins. The firm’s lead candidate and sole clinical asset, […]

Venaxis to merge with Strand Life Sciences

Venaxis to merge with Strand Life Sciences

January 27, 2016 by · Leave a Comment 

Tweet Venaxis (NASDAQ:APPY) has entered into a series of agreements for a transaction with Strand Life Sciences Private Limited and its shareholders. Strand is a privately-held, global genomics and bioinformatics company based in India. The effect of the transaction will be that Strand shareholders and the employees and directors who are option-holders in Strand will own […]

Next Page »

Email Newsletters with Constant Contact
Google+